Low sensitivity to EGFR inhibitors was confirmed in these KRAS mutated PDOs, both relative to other anti-cancer agents and relative to RAS wild-type PDOs in the reference dataset (Fig. 2A and D). This evidence concerns the gene KRAS and cancer.